Related Experiment Video

Updated: Jul 5, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib

David Hong1, Lei Ye, Robert Gagel

  • 1Department of Investigational Therapeutics (Phase I Program), Unit 455, Division of Cancer Medicine, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. dshong@mdanderson.org

Molecular Cancer Therapeutics
|May 1, 2008
PubMed

Insights

Medullary thyroid carcinoma (MTC) treatment remains challenging. A patient with advanced MTC and a novel RET aberration responded rapidly to sorafenib-based therapy, offering new hope.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Medullary thyroid carcinoma (MTC) is a rare cancer with limited treatment options for advanced stages.
  • RET proto-oncogene mutations are key drivers in both familial and sporadic MTC.
  • Current therapies are ineffective for recurrent or metastatic MTC.

Observation:

  • A patient with sporadic MTC presented with advanced, progressive disease.
  • Tumor tissue analysis revealed a novel RET kinase aberration at exon 11.
  • The patient received a treatment regimen based on sorafenib, a multi-kinase inhibitor.

Findings:

  • The patient exhibited a rapid and significant response to the sorafenib-based regimen.
  • This suggests a potential therapeutic benefit of targeting RET aberrations in MTC.
  • The novel RET aberration may predict sensitivity to kinase inhibitors.

Implications:

  • Sorafenib-based therapy shows promise for treating advanced MTC with specific RET alterations.
  • This case highlights the importance of molecular profiling in MTC for personalized treatment strategies.
  • Further research into RET-targeted therapies could improve outcomes for MTC patients.

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...